News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

|Videos|February 13, 2023

CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Updated Efficacy Outcomes

Author(s)Brian I. Rini, MD, Hans Hammers, MD, Tian Zhang, MD

Brian Rini, MD, presents updated data from the CLEAR trial of lenvatinib plus pembrolizumab versus sunitinib in frontline advanced renal cell carcinoma.

Episodes in this series

EP. 1 CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Updated Efficacy Outcomes

EP. 1 CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Updated Efficacy Outcomes

EP. 2 CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Additional Findings

EP. 2 CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Additional Findings

EP. 3 Observing Patients with Advanced Renal Cell Carcinoma Before Systemic Therapy

EP. 3 Observing Patients with Advanced Renal Cell Carcinoma Before Systemic Therapy

EP. 4 Impact of the CLEAR Trial Data Updates in Clinical Practice

EP. 4 Impact of the CLEAR Trial Data Updates in Clinical Practice

EP. 5 Approaches to the Frontline Treatment of Advanced Kidney Cancer

EP. 5 Approaches to the Frontline Treatment of Advanced Kidney Cancer

EP. 6 Switching a Patient with Advanced RCC Between IO + TKI and IO + IO Combination Regimens

EP. 6 Switching a Patient with Advanced RCC Between IO + TKI and IO + IO Combination Regimens

EP. 7 Approaches to Dosing TKIs in Patients with Advanced RCC

EP. 7 Approaches to Dosing TKIs in Patients with Advanced RCC

EP. 8 COSMIC-313 Trial of Cabozantinib, Nivolumab and Ipilimumab in Frontline Advanced RCC

EP. 8 COSMIC-313 Trial of Cabozantinib, Nivolumab and Ipilimumab in Frontline Advanced RCC

EP. 9 Phase III Trial of Lenvatinib, Pembrolizumab, and Belzutifan or Quavonlimab in Frontline Advanced RCC

EP. 9 Phase III Trial of Lenvatinib, Pembrolizumab, and Belzutifan or Quavonlimab in Frontline Advanced RCC

EP. 10 Clinical Trials in Adjuvant IO Therapy for RCC

EP. 10 Clinical Trials in Adjuvant IO Therapy for RCC

EP. 11 Disease Progression After Adjuvant Pembrolizumab Therapy for RCC

EP. 11 Disease Progression After Adjuvant Pembrolizumab Therapy for RCC

EP. 12 Frontline Therapy for Non-Clear Cell RCC

EP. 12 Frontline Therapy for Non-Clear Cell RCC

Recap: CLEAR Trial Regimen as a Standard for Frontline Clear Cell RCC: Impressive Efficacy but Personalization Is Needed

EP. 13 Recap: CLEAR Trial Regimen as a Standard for Frontline Clear Cell RCC: Impressive Efficacy but Personalization Is Needed

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related Content

Trending on CancerNetwork

Spotlighting the Top 10 FDA Oncology Approvals in 2025

Ivosidenib Combo Shows Preliminary Activity in IDH1-Mutated AML

Nab-Sirolimus Regimens Show Promise in HR+/HER2-Negative Breast Cancer

What’s New in Hematology/Oncology? Discussing the 2025 ASH Annual Meeting

‘Relatively Low’ AEs Noted With Durvalumab/FLOT in Gastric/GEJ Cancer